Try GOLD - Free

“Our ambition requires us to take long-term view, investing in scale and building unmatched capabilities”

BioSpectrum Asia

|

January 2023

The novel trend in single-cell analysis is revolutionising biological research, unravelling underlying genetic credentials while creating new therapeutic approaches and personalised treatments.

- Hithaishi C Bhaskar

“Our ambition requires us to take long-term view, investing in scale and building unmatched capabilities”

For it to become more feasible, powerful, reliable tools can fuel scientific discoveries and drive exponential progress to refine genetic analysis for developing better treatment regimens. A study by Grand View Research reveals that the global single-cell analysis market size was valued at 3.28 billion in 2021 and is expected to expand at a compound annual growth rate CAGR) of 18.5 per cent from 2022 to 2030. Aware of the burgoing growth of single-cell-analysis market, Dr Ben Hindson, President Co-Founder of 10x Genomics explains how innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more areas using innovative diagnosis and therapy techniques.

What are the drivers and trends shaping the single-cell-analysis market? How do you Identify growth segments for investment and expansion?

More and more, we see that single cell methods are becoming the standard for a growing fraction of life science research, an essential element of many new grant applications and are increasingly becoming a requirement for publication.

Our goal at 10x Genomics is to make single cell analysis accessible to every biology lab in the world to make it the standard for most biological research.

Since the initial launch of our Single Cell Gene Expression solution, we have released many new capabilities and versions of our products focused on expanding the range of applications on the platform, including immune-profiling, epigenetics, proteins and multi-omics.

We have expanded the fundamental capabilities of the platform, highlighted by the release of the Chromium X instrument, which has made it possible for people to run up to 1 million cell experiments routinely.

MORE STORIES FROM BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Translate

Share

-
+

Change font size